Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Gout: HELP
Articles from California
Based on 272 articles published since 2009
||||

These are the 272 published articles about Gout that originated from California during 2009-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11
1 Guideline ACR Appropriateness Criteria 2017

Anonymous3950905 / Jacobson, Jon A / Roberts, Catherine C / Bencardino, Jenny T / Appel, Marc / Arnold, Erin / Baccei, Steven J / Cassidy, R Carter / Chang, Eric Y / Fox, Michael G / Greenspan, Bennett S / Gyftopoulos, Soterios / Hochman, Mary G / Mintz, Douglas N / Newman, Joel S / Rosenberg, Zehava S / Shah, Nehal A / Small, Kirstin M / Weissman, Barbara N. ·Principal Author, University of Michigan Medical Center, Ann Arbor, Michigan. Electronic address: jjacobsn@umich.edu. · Panel Chair, Mayo Clinic, Phoenix, Arizona. · Panel Vice-Chair, New York University School of Medicine, New York, New York. · James J. Peters VA Medical Center, Bronx, New York, American Academy of Orthopaedic Surgeons. · Orthopaedics and Rheumatology of the North Shore, Skokie, Illinois. American College of Rheumatology. · UMass Memorial Medical Center, Worcester, Massachusetts. · UK Healthcare Spine and Total Joint Service, Lexington, Kentucky. American Academy of Orthopaedic Surgeons. · VA San Diego Healthcare System, San Diego, California. · University of Virginia Health System, Charlottesville, Virginia. · Medical College of Georgia at Augusta University, Augusta, Georgia. · New York University Medical Center, New York, New York. · Beth Israel Deaconess Medical Center, Boston, Massachusetts. · Hospital for Special Surgery, New York, New York. · New England Baptist Hospital, Boston, Massachusetts. · Hospital for Joint Diseases, New York, New York. · Brigham & Women's Hospital, Boston, Massachusetts. · Specialty Chair, Brigham & Women's Hospital, Boston, Massachusetts. ·J Am Coll Radiol · Pubmed #28473097.

ABSTRACT: Evaluation for suspected inflammatory arthritis as a cause for chronic extremity joint pain often relies on imaging. This review first discusses the characteristic osseous and soft tissue abnormalities seen with inflammatory arthritis and how they may be imaged. It is essential that imaging results are interpreted in the context of clinical and serologic results to add specificity as there is significant overlap of imaging findings among the various types of arthritis. This review provides recommendations for imaging evaluation of specific types of inflammatory arthritis, including rheumatoid arthritis, seronegative spondyloarthropathy, gout, calcium pyrophosphate dihydrate disease (or pseudogout), and erosive osteoarthritis. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer-reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.

2 Editorial PPARGC1B: insight into the expression of the gouty inflammation phenotype: PPARGC1B and gouty inflammation. 2017

Merriman, Tony / Terkeltaub, Robert. ·Department of Biochemistry, University of Otago, Dunedin, New Zealand. · VA San Diego Healthcare System. · Department of Medicine, University of California San Diego, San Diego, CA, USA. ·Rheumatology (Oxford) · Pubmed #28003496.

ABSTRACT: -- No abstract --

3 Editorial Editorial: Do Not Let Gout Apathy Lead to Gouty Arthropathy. 2017

FitzGerald, John D / Neogi, Tuhina / Choi, Hyon K. ·University of California, Los Angeles. · Boston University, Boston, Massachusetts. · Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. ·Arthritis Rheumatol · Pubmed #28002890.

ABSTRACT: -- No abstract --

4 Editorial Emerging uricosurics for gout. 2017

Terkeltaub, Robert. ·a Department of Medicine, VA San Diego Healthcare System , University of California San Diego , La Jolla , CA , USA. ·Expert Rev Clin Pharmacol · Pubmed #27937050.

ABSTRACT: -- No abstract --

5 Editorial Is It Time to Start Treating Asymptomatic Hyperuricemia? 2015

Levy, Gerald / Cheetham, T Craig. ·Southern California Permanente Medical Group, Downey, California. Electronic address: gerald.d.levy@kp.org. · Southern California Permanente Medical Group, Pasadena, California. ·Am J Kidney Dis · Pubmed #26593311.

ABSTRACT: -- No abstract --

6 Editorial Good Intentions, Unintended Consequences, and Unrealized Benefits. 2015

FitzGerald, John D. ·David Geffen School of Medicine, Department of Medicine, Division of Rheumatology, Rehabilitation Center, University of California at Los Angeles, Room 32-59, Los Angeles, CA, 90095-1670, USA. JFitzgerald@mednet.ucla.edu. ·J Gen Intern Med · Pubmed #26239629.

ABSTRACT: -- No abstract --

7 Editorial Editorial: Can GPR43 Sensing of Short-Chain Fatty Acids Unchain Inflammasome-Driven Arthritis? 2015

Haslberger, Alexander / Terkeltaub, Robert. ·University of Vienna, Vienna, Austria. · VA San Diego Healthcare System, San Diego, California, and University of California at San Diego, La Jolla, California. ·Arthritis Rheumatol · Pubmed #25914362.

ABSTRACT: -- No abstract --

8 Editorial Gout and crystal arthropathies. 2014

Weisman, Michael H. ·Division of Rheumatology, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90024, USA. Electronic address: michael.weisman@cshs.org. ·Rheum Dis Clin North Am · Pubmed #24703354.

ABSTRACT: -- No abstract --

9 Editorial Apolipoprotein a-I at the interface of vascular inflammation and arthritis. 2014

Terkeltaub, Robert. ·From San Diego VA Healthcare System and Department of Medicine, University of California, San Diego, CA. ·Arterioscler Thromb Vasc Biol · Pubmed #24554604.

ABSTRACT: -- No abstract --

10 Review Modifiable risk and protective factors in disease development, progression and clinical subtypes of Parkinson's disease: What do prospective studies suggest? 2019

Belvisi, Daniele / Pellicciari, Roberta / Fabbrini, Giovanni / Tinazzi, Michele / Berardelli, Alfredo / Defazio, Giovanni. ·IRCCS Neuromed, via Atinense 18, 86077 Pozzilli, IS, Italy. · Department of Basic Medical Sciences, Neuroscience and Sense Organs, "Aldo Moro", University of Bari, Bari, Italy. · IRCCS Neuromed, via Atinense 18, 86077 Pozzilli, IS, Italy; Department of Human Neurosciences, Sapienza University of Rome, Viale dell' Università 30, 00185 Rome, Italy. · Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Via Casorati 43, 37131 Verona, Italy. · IRCCS Neuromed, via Atinense 18, 86077 Pozzilli, IS, Italy; Department of Human Neurosciences, Sapienza University of Rome, Viale dell' Università 30, 00185 Rome, Italy. Electronic address: alfredo.berardelli@uniroma1.it. · Department of Medical Sciences and Public Health, University of Cagliari, SS 554 bivio Sestu, 09042 Monserrato, CA, Italy. ·Neurobiol Dis · Pubmed #31706021.

ABSTRACT: Parkinson's disease (PD) is a neurodegenerative disorder whose pathogenesis depends on a combination of genetic and environmental factors. The aim of the present review was to provide an updated description of the findings emerging from prospective longitudinal cohort studies on the possible risk/protective factors underlying the development, progression and clinical subtypes of PD. We reviewed all the environmental, lifestyle, dietary, comorbid and pharmacological factors that have been investigated as possible modifiable protective/risk factors for PD by longitudinal studies. Only a few factors have the epidemiological evidence and the biological plausibility to be considered risk (pesticides, dairy products, β2-adrenoreceptor antagonists) or protective (smoking, caffeine and tea intake, physical activity, gout, vitamin E intake, non-steroidal anti-inflammatory drugs and β2-adrenoreceptor agonists) factors for PD. Caffeine intake and physical activity also seem to slow down the progression of the disease, thus representing good candidates for primary prevention and disease modifying strategies in PD. Possible modifiable risk factors of PD subtypes is almost unknown and this might depend on the uncertain biological and neuropathological reliability of clinical subtypes. The results of the present review suggest that only eleven risk/protective factors may be associated with the risk of PD. It may be possible to target some of these factors for preventive interventions aimed at reducing the risk of developing and the rate of progression of PD.

11 Review Tophaceous Gout of the Middle Ear: Case Reports and Review of the Literature. 2019

Saliba, Joe / Sakano, Hitomi / Friedman, Rick A / Harris, Jeffrey P. ·Department of Surgery, Division of Otolaryngology, Head and Neck Surgery, University of California - San Diego, San Diego, California, USA. · Department of Otolaryngology, University of Rochester Medical Center, Rochester, New York, USA. · Department of Surgery, Division of Otolaryngology, Head and Neck Surgery, University of California - San Diego, San Diego, California, USA, jpharris@ucsd.edu. ·Audiol Neurootol · Pubmed #31167187.

ABSTRACT: Tophaceous gout of the middle ear is a rare occurrence that presents as a granular white-colored mass. It is frequently misdiagnosed as cholesteatoma or tympanosclerosis in patients who otherwise may not manifest any clinical or biochemical signs of gout. While uncommon, it can lead to clinically significant disease such as conductive hearing loss. The present report describes 2 cases of middle ear gouty tophi initially mistaken for another entity. Both patients underwent surgery, and the diagnosis of gout was revealed after final histopathological analysis. A review of the literature is also presented.

12 Review Joint Clinical Consensus Statement of the American College of Foot and Ankle Surgeons® and the American Association of Nurse Practitioners®: Etiology, Diagnosis, and Treatment Consensus for Gouty Arthritis of the Foot and Ankle. 2018

Mirmiran, Roya / Bush, Tom / Cerra, Michele M / Grambart, Sean / Kauschinger, Elaine / Younger, Melissa / Zychowicz, Michael. ·Foot and Ankle Surgeon, Department of Surgery, Sutter Medical Group, Sacramento, CA. Electronic address: Roya.Mirmiran@aol.com. · Associate Professor and Assistant Dean for Practice, University of North Carolina at Chapel Hill Schools of Nursing and Medicine, Chapel Hill, NC. · Director of the Duke NP/PA Rheumatology Fellowship Program & Faculty, Department of Medicine, Duke University School of Medicine, NC. · Foot and Ankle Surgeon, Carle Physician Group, Department of Surgery, Champaign, IL. · Clinical Assistant Professor, Duke University School of Nursing, Durham, NC. · Podiatric Research Fellow, Penn Presbyterian Medical Center, Philadelphia, PA. · Professor and Director of MSN Program & Lead Faculty in Orthopedic NP Specialty, Duke University School of Nursing, Durham, NC. ·J Foot Ankle Surg · Pubmed #30368431.

ABSTRACT: Gout is a condition that commonly affects the foot and ankle, and practitioners who treat these structures should be aware of the methods to diagnose and treat this form of arthritis. Practitioners also need to recognize extra-articular manifestations of the disease. Although the acutely red, hot, swollen joint is a common presentation, chronic tophaceous gout can be associated with pain, nodule formation, and cutaneous compromise. Since the underlying causes that lead to excessive monosodium urate deposition may be treatable, early and accurate diagnosis can be very beneficial and may even prevent articular degeneration.

13 Review Evidence for Transient Receptor Potential (TRP) Channel Contribution to Arthritis Pain and Pathogenesis. 2018

Galindo, Tabitha / Reyna, Jose / Weyer, Andy. ·School of Physical Therapy and Athletic Training, Pacific University, Hillsboro, OR 97116, USA. tdgalindo@pacificu.edu. · School of Physical Therapy and Athletic Training, Pacific University, Hillsboro, OR 97116, USA. reyn1741@pacificu.edu. · Biological Sciences Department, City College of San Francisco, San Francisco, CA 94112, USA. aweyer@ccsf.edu. ·Pharmaceuticals (Basel) · Pubmed #30326593.

ABSTRACT: Based on clinical and preclinical evidence, Transient Receptor Potential (TRP) channels have emerged as potential drug targets for the treatment of osteoarthritis, rheumatoid arthritis, and gout. This review summarizes the relevant data supporting a role for various TRP channels in arthritis pain and pathogenesis, as well as the current state of pharmacological efforts to ameliorate arthritis symptoms in patient populations.

14 Review Characterization of the xanthine oxidase inhibitory activity of alk(en)yl phenols and related compounds. 2018

Masuoka, Noriyoshi / Kubo, Isao. ·CDW Life Science Lab, Okayama Research Park Incubation Center, 5303 Haga, Kita-ku, Okayama 701-1221, Japan; Department of Life Science, Faculty of Science, Okayama University of Science, Japan. Electronic address: masuokan@ms11.megaegg.ne.jp. · Department of Environmental Science, Policy and Management, University of California, Berkeley, CA 94720-3114, USA. ·Phytochemistry · Pubmed #30096514.

ABSTRACT: The inhibitory activity of xanthine oxidase (XO) is a combination of uric acid formation inhibition and superoxide anion (O

15 Review Review: Unmet Needs and the Path Forward in Joint Disease Associated With Calcium Pyrophosphate Crystal Deposition. 2018

Abhishek, Abhishek / Neogi, Tuhina / Choi, Hyon / Doherty, Michael / Rosenthal, Ann K / Terkeltaub, Robert. ·University of Nottingham, UK City Hospital, Nottingham, UK. · Boston University School of Medicine, Boston, Massachusetts. · Massachusetts General Hospital, Boston, Massachusetts. · Medical College of Wisconsin, Milwaukee. · Veterans Affairs, University of California at San Diego, San Diego, California. ·Arthritis Rheumatol · Pubmed #29609209.

ABSTRACT: Calcium pyrophosphate (CPP) crystal deposition (CPPD) is prevalent and can be associated with synovitis and joint damage. The population of elderly persons predominantly affected by CPPD is growing rapidly. Since shortfalls exist in many aspects of CPPD, we conducted an anonymous survey of CPPD unmet needs, prioritized by experts from the Gout, Hyperuricemia and Crystal-Associated Disease Network. We provide our perspectives on the survey results, and we propose several CPPD basic and clinical translational research pathways. Chondrocyte and cartilage culture systems for generating CPP crystals in vitro and transgenic small animal CPPD models are needed to better define CPPD mechanism paradigms and help guide new therapies. CPPD recognition, clinical research, and care would be improved by international consensus on CPPD nomenclature and disease phenotype classification, better exploitation of advanced imaging, and pragmatic new point-of-care crystal analytic approaches for detecting CPP crystals. Clinical impacts of CPP crystals in osteoarthritis and in asymptomatic joints in elderly persons remain major unanswered questions that are rendered more difficult by current inability to therapeutically limit or dissolve the crystal deposits and assess the consequent clinical outcome. Going forward, CPPD clinical research studies should define clinical settings in which articular CPPD does substantial harm and should include analyses of diverse clinical phenotypes and populations. Clinical trials should identify the best therapeutic targets to limit CPP crystal deposition and associated inflammation and should include assessment of intraarticular agents. Our perspective is that such advances in basic and clinical science in CPPD are now within reach and can lead to better treatments for this disorder.

16 Review Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation. 2018

Johnson, Richard J / Bakris, George L / Borghi, Claudio / Chonchol, Michel B / Feldman, David / Lanaspa, Miguel A / Merriman, Tony R / Moe, Orson W / Mount, David B / Sanchez Lozada, Laura Gabriella / Stahl, Eli / Weiner, Daniel E / Chertow, Glenn M. ·University of Colorado, Denver, CO. · University of Chicago Medicine, Chicago, IL. · University of Bologna, Bologna, Italy. · National Kidney Foundation, New York City, NY. · University of Otago, Dunedin, NZ. · University of Texas Southwestern Medical Center, Dallas, TX. · Brigham and Women's Hospital, Harvard Medical School, Boston, MA. · Instituto Nacional de Cardiología, Ignacio Chávez, Mexico City, Mexico. · Mount Sinai School of Medicine, New York City, NY. · Tufts Medical Center, Boston, MA. · Stanford University, Stanford, CA. Electronic address: gchertow@stanford.edu. ·Am J Kidney Dis · Pubmed #29496260.

ABSTRACT: Urate is a cause of gout, kidney stones, and acute kidney injury from tumor lysis syndrome, but its relationship to kidney disease, cardiovascular disease, and diabetes remains controversial. A scientific workshop organized by the National Kidney Foundation was held in September 2016 to review current evidence. Cell culture studies and animal models suggest that elevated serum urate concentrations can contribute to kidney disease, hypertension, and metabolic syndrome. Epidemiologic evidence also supports elevated serum urate concentrations as a risk factor for the development of kidney disease, hypertension, and diabetes, but differences in methodologies and inpacts on serum urate concentrations by even subtle changes in kidney function render conclusions uncertain. Mendelian randomization studies generally do not support a causal role of serum urate in kidney disease, hypertension, or diabetes, although interpretation is complicated by nonhomogeneous populations, a failure to consider environmental interactions, and a lack of understanding of how the genetic polymorphisms affect biological mechanisms related to urate. Although several small clinical trials suggest benefits of urate-lowering therapies on kidney function, blood pressure, and insulin resistance, others have been negative, with many trials having design limitations and insufficient power. Thus, whether uric acid has a causal role in kidney and cardiovascular diseases requires further study.

17 Review Association between ABCG2 rs2231142 and poor response to allopurinol: replication and meta-analysis. 2018

Wallace, Mary C / Roberts, Rebecca L / Nanavati, Payal / Miner, Jeffrey N / Dalbeth, Nicola / Topless, Ruth / Merriman, Tony R / Stamp, Lisa K. ·Department of Surgical Sciences, University of Otago, Dunedin, New Zealand. · Biology Department, Ardea Biosciences, Inc., San Diego, CA, USA. · Department of Medicine, University of Auckland, Auckland, New Zealand. · Department of Biochemistry, University of Otago, Dunedin, New Zealand. · Department of Medicine, University of Otago, Christchurch, New Zealand. ·Rheumatology (Oxford) · Pubmed #29342288.

ABSTRACT: Objective: ABCG2 rs2231142 (Q141K) has been reported to be associated with poor response to allopurinol, while there are conflicting data on the association between the genetically independent ABCG2 rs10011796 variant and allopurinol response. The aim of this study was to replicate the association of ABCG2 rs2231142 and rs10011796 with allopurinol response and perform a meta-analysis. Methods: Participants in the Long-term Allopurinol Safety Study Evaluating Outcomes in Gout Patients (LASSO) (n = 299) were studied. In patients with evidence of adherence to allopurinol therapy (plasma oxypurinol >20 μmol/l), good response was defined as serum urate <6 mg/dl on allopurinol ⩽300 mg/day and poor response as serum urate ⩾ 6 mg/dl despite allopurinol >300 mg/day. Association of rs2231142 and rs10011796 with poor response was tested in logistic regression models that included age, sex, BMI, ethnicity and estimated glomerular filtration rate. Results from the LASSO study and a subset of participants in the Genetics of Gout in Aotearoa New Zealand study (n = 296, including 264 from a previously published report) were combined by meta-analysis. Results: There was evidence for association of rs2231142 with allopurinol response [odds ratio (OR) = 2.35, P = 7.3 × 10-4] but not for rs10011796 (OR = 1.21, P = 0.33) in the LASSO cohort using an adjusted logistic regression model. Meta-analysis provided evidence of a significant association of rs2231142 with allopurinol response (OR = 2.43, P = 6.2 × 10-7), but not rs10011796 (OR = 1.06, P = 0.69). Conclusion: This study has confirmed the significant association of ABCG2 rs2231142 with poor response to allopurinol.

18 Review Cannabis Roots: A Traditional Therapy with Future Potential for Treating Inflammation and Pain. 2017

Ryz, Natasha R / Remillard, David J / Russo, Ethan B. ·Ryz Rémi, Vancouver, Canada. · PHYTECS, Los Angeles, California. ·Cannabis Cannabinoid Res · Pubmed #29082318.

ABSTRACT:

19 Review What makes gouty inflammation so variable? 2017

Terkeltaub, Robert. ·VA San Diego Healthcare System, 111K, 3350 La Jolla Village Drive, San Diego, CA, 92161, USA. rterkeltaub@ucsd.edu. · Department of Medicine, University of California San Diego, San Diego, CA, USA. rterkeltaub@ucsd.edu. ·BMC Med · Pubmed #28818081.

ABSTRACT: Acute gout arthritis flares contribute dominantly to gout-specific impaired health-related quality of life, representing a progressively increasing public health problem. Flares can be complex and expensive to treat, partly due to the frequent comorbidities. Unmet needs in gout management are more pressing given the markedly increasing gout flare hospital admission rates. In addition, chronic gouty arthritis can cause joint damage and functional impairment. This review addresses new knowledge on the basis for the marked, inherent variability of responses to deposited urate crystals, including the unpredictable and self-limited aspects of many gout flares. Specific topics reviewed include how innate immunity and two-signal inflammasome activation intersect with diet, metabolism, nutritional biosensing, the microbiome, and the phagocyte cytoskeleton and cell fate. The paper discusses the roles of endogenous constitutive regulators of inflammation, including certain nutritional biosensors, and emerging genetic and epigenetic factors. Recent advances in the basis of variability in responses to urate crystals in gout provide information about inflammatory arthritis, and have identified potential new targets and strategies for anti-inflammatory prevention and treatment of gouty arthritis.

20 Review Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN). 2017

Dalbeth, Nicola / Bardin, Thomas / Doherty, Michael / Lioté, Frédéric / Richette, Pascal / Saag, Kenneth G / So, Alexander K / Stamp, Lisa K / Choi, Hyon K / Terkeltaub, Robert. ·Department of Medicine, University of Auckland, 85 Park Road, Grafton, Auckland 1023, New Zealand. · University Paris Diderot Cité Sorbonne, Service de Rhumatologie, Centre Viggo Petersen, Lariboisière Hospital, INSERM U1132, Paris, France. · Division of Rheumatology, Orthopaedics and Dermatology, School of Medicine, University of Nottingham, Clinical Sciences Building, City Hospital, Nottingham NG5 1PB, UK. · Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham (UAB), 820 Faculty Office Tower, 510 20th Street, Birmingham, Alabama 35294-3408, USA. · Service of Rheumatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Avenue Pierre Decker 4, 1011 Lausanne, Switzerland. · Department of Medicine, University of Otago, Christchurch, P.O. BOX 4345, Christchurch 8140, New Zealand. · Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, 55 Fruit Street, Harvard Medical School, Boston, Massachusetts 02114, USA. · VA San Diego Healthcare System, 111K, 3350 La Jolla Village Drive, San Diego, California 92161, USA. ·Nat Rev Rheumatol · Pubmed #28794514.

ABSTRACT: In November 2016, the American College of Physicians (ACP) published a clinical practice guideline on the management of acute and recurrent gout. This guideline differs substantially from the latest guidelines generated by the American College of Rheumatology (ACR), European League Against Rheumatism (EULAR) and 3e (Evidence, Expertise, Exchange) Initiative, despite reviewing largely the same body of evidence. The Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) convened an expert panel to review the methodology and conclusions of these four sets of guidelines and examine possible reasons for discordance between them. The G-CAN position, presented here, is that the fundamental pathophysiological knowledge underlying gout care, and evidence from clinical experience and clinical trials, supports a treat-to-target approach for gout aimed at lowering serum urate levels to below the saturation threshold at which monosodium urate crystals form. This practice, which is truly evidence-based and promotes the steady reduction in tissue urate crystal deposits, is promoted by the ACR, EULAR and 3e Initiative recommendations. By contrast, the ACP does not provide a clear recommendation for urate-lowering therapy (ULT) for patients with frequent, recurrent flares or those with tophi, nor does it recommend monitoring serum urate levels of patients prescribed ULT. Results from emerging clinical trials that have gout symptoms as the primary end point are expected to resolve this debate for all clinicians in the near term future.

21 Review Dual Energy Computed Tomography Applications for the Evaluation of the Spine. 2017

Komlosi, Peter / Wintermark, Max. ·Department of Radiology, University of Pittsburgh, 200 Lothrop Street, 2nd Floor, Suite 200 East Wing, Pittsburgh, PA 15213, USA. Electronic address: komlosip@upmc.edu. · Department of Radiology, Stanford University School of Medicine, 300 Pasteur Drive, S047 MC 5105, Stanford, CA 94305, USA. ·Neuroimaging Clin N Am · Pubmed #28711207.

ABSTRACT: Capturing the energy-dependent x-ray attenuation of different tissues, dual-energy computed tomography offers multiple benefits in the imaging of the spine, such as bone and iodinated contrast removal, monosodium urate imaging, and robust reduction of beam-hardening artifacts. The emerging new applications of this technique include bone marrow imaging in acute trauma and myeloinfiltrative disorders, improved bone density determination, and noninvasive assessment of spinal gout.

22 Review Serum uric acid levels and multiple health outcomes: umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies. 2017

Li, Xue / Meng, Xiangrui / Timofeeva, Maria / Tzoulaki, Ioanna / Tsilidis, Konstantinos K / Ioannidis, John PA / Campbell, Harry / Theodoratou, Evropi. ·Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh EH8 9AG, UK. · Colon Cancer Genetics Group, Medical Research Council Human Genetics Unit, Medical Research Council Institute of Genetics & Molecular Medicine, University of Edinburgh, Edinburgh, UK. · Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK. · Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece. · Stanford Prevention Research Center, Stanford School of Medicine, Stanford, CA, USA. · Department of Health Research and Policy, Stanford School of Medicine, Stanford, CA, USA. · Department of Statistics, Stanford University, Stanford, CA, USA. · Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh EH8 9AG, UK E.Theodoratou@ed.ac.uk. ·BMJ · Pubmed #28592419.

ABSTRACT:

23 Review Managing kidney transplant recipients in primary care. 2017

Roth, Shira. ·Shira Roth practices general nephrology at Stanford University Hospital in Stanford, Calif., after completing a fellowship in abdominal organ transplant at Mayo Clinic in Phoenix, Ariz. The author has disclosed no potential conflicts of interest, financial or otherwise. ·JAAPA · Pubmed #28538426.

ABSTRACT: Patients who have undergone kidney transplant are at increased risk for heart disease, new-onset diabetes, metabolic syndrome, and certain malignancies, in addition to opportunistic infections associated with immunosuppression. This article describes guidelines for routine management of kidney transplant recipients in primary care, as well as how to recognize risk factors and complications.

24 Review Treatment approaches and adherence to urate-lowering therapy for patients with gout. 2017

Aung, Thanda / Myung, Gihyun / FitzGerald, John D. ·Division of Rheumatology/Department of Internal Medicine, University of California, Los Angeles, Los Angeles, CA, USA. ·Patient Prefer Adherence · Pubmed #28458524.

ABSTRACT: Gout is the most common inflammatory arthritis characterized by painful disabling acute attacks. It is caused by hyperuricemia and deposition of urate crystals in and around the joints. Long-standing untreated hyperuricemia can lead to chronic arthritis with joint damage, tophi formation and urate nephropathy. Gout is associated with significant morbidity and health care associated cost. The goal of long-term therapy is to lower the serum urate level to promote dissolution of urate crystals, reduce recurrent acute gout flares, resolve tophi and prevent joint damage. Despite the presence of established gout treatment guidelines and effective medications to manage gout, patient outcomes are often poor. Etiology for these shortcomings is multifactorial including both physician and patient characteristics. Poor adherence to urate-lowering therapy (ULT) is prevalent and is a significant contributor to poor patient outcomes. This article reviews the treatment strategies for the management of hyperuricemia in chronic gout, gaps in quality of care in gout management, factors contributing to poor adherence to ULT and discusses potential interventions to achieve improved gout-related outcomes. These interventions include initiation of prophylactic anti-inflammatory medication when starting ULT, frequent follow-ups, regular serum urate monitoring and improved patient education, which can be achieved through pharmacist- or nurse-assisted programs. Interventions such as these could improve adherence to ULT and, ultimately, result in optimal gout-related outcomes.

25 Review Did King Herod suffer from a rheumatic disease? 2017

Leatherwood, Cianna / Panush, Richard S. ·Department of Medicine, the Keck School of Medicine, University of Southern California and USC+LAC Medical Center, Los Angeles, CA, USA. · Department of Rheumatology, Brigham and Women's Hospital, Boston, MA, 02115, USA. · Division of Rheumatology, Department of Medicine, the Keck School of Medicine, University of Southern California and USC+LAC Medical Center, Los Angeles, CA, 90033, USA. panush@usc.edu. ·Clin Rheumatol · Pubmed #28243759.

ABSTRACT: Herod the Great was appointed "king of Jews," to govern Judea, by the Roman Emperor and Senate. He lived from 73/74 BCE to 4 CE. He died with an illness and symptoms that have been the source of considerable speculation. Richard Strauss depicted Herod in his classic opera, "Salome." That opera was derived from a play of the same name by Oscar Wilde, which was based on an 1876 painting, "Salome Dancing Before Herod," by Gustave Moreau. The operatic Herod was afflicted with an illness characterized by dementia, hallucinations, paranoia, alcoholism (from drinking the Emperor's wine), violence, twitches, and sterility; different interpretations showed him also with falls, chills, shaking, thirst, forgetfulness, and sleepiness, for which we suggest the novel diagnosis of chronic lead intoxication (which can manifest to rheumatologists as saturnine gout). He had compatible symptoms (encephalopathy and neuromuscular abnormalities) and consumed excessive quantities of imperial wine, known to be highly contaminated with lead and likely associated with similar symptoms among Roman aristocracy. Herod's demented cruelties-an oppressive reign which including the beheading of John the Baptist-exacerbated the political climate and may have contributed to the subsequent violent 7-year revolt culminating in the destruction of the second temple. How different might history have been if Herod the Great had been abstemious?

Next